Document is current
Any future updates will be listed below
-
Authors
Hurzeler, Tristan
Logge, Warren
Watt, Joshua
McGregor, I. S.
Suraev, Anastasia
Haber, Paul S.
Morley, Kirsten C. https://orcid.org/0000-0002-0868-9928
-
Funding
Funding for this research was provided by:
University of Sydney
- License Information
-
More Information
Article History
Received: 8 July 2024
Accepted: 12 February 2025
First Online: 18 March 2025
Declarations
:
: T.H., W.L., J.W., P.H., and K.M.have no competing interests to disclose. ISM is Academic Director of the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically funded research program at the University of Sydney. He has served as an expert witness in various medicolegal cases involving cannabis and has received consulting fees from Medical Cannabis Industry Australia (MCIA) and Janssen. He currently acts as an advisor/consultant to Kinoxis Therapeutics, Psylo and Emyria. He reports research grants and salary support from the Australian National Health and Medical Research Council (NHMRC) and from Lambert Initiative for Cannabinoid Therapeutics. He is an inventor on patents WO2018107216A1 and WO2017004674A1, licensed to Kinoxis Therapeutics involving use of novel small molecules (non-cannabinoid) to treat addictions and social deficits. ISM also has patents WO2020102857A1 and WO2021042178A1 related to use of small molecules (non-cannabinoid) for treating weight gain and opioid withdrawal, as well as patents WO2019227167 and WO2019071302 issued, which relate to cannabinoid therapeutics. AS has received consulting fees from the Medical Cannabis Industry Australia (MCIA) and Haleon (consumer healthcare subsidiary of Glaxo Smith-Kline).
